| DIRECT COMPETITOR COMPARISON | |
| PTN | AMLN | Pvt1 | VVUS | Industry | | Market Cap: | 25.97M | 1.96B | N/A | 662.11M | 62.33M | | Employees: | 43 | 1,800 | 2,0791 | 130 | 56 | | Qtrly Rev Growth (yoy): | 385.90% | -3.30% | N/A | -82.60% | 18.90% | | Revenue (ttm): | 14.26M | 816.77M | 175.00M1 | 70.19M | 12.73M | | Gross Margin (ttm): | 13.27% | 59.56% | N/A | 83.21% | 50.63% | | EBITDA (ttm): | -1.76M | -125.22M | N/A | -41.42M | -1.76M | | Oper Margins (ttm): | -21.75% | -19.59% | N/A | -60.65% | -19.80% | | Net Income (ttm): | -556.78K | -234.68M | N/A | -47.77M | N/A | | EPS (ttm): | -0.006 | -1.680 | N/A | -0.683 | N/A | | P/E (ttm): | N/A | N/A | N/A | N/A | 23.64 | | PEG (5 yr expected): | N/A | N/A | N/A | N/A | 1.36 | | P/S (ttm): | 1.82 | 2.41 | N/A | 9.70 | 3.09 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.42 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | AMLN | | Byetta Label Revised
Fri, Nov 27 -
Zacks.com | | • | AMLN | | A Big Upgrade for Amylin Pharmaceuticals
Wed, Nov 25 -
at Motley Fool | | • | AMLN | | If You Could Love Only One Stock
Tue, Nov 24 -
at Forbes.com | | • | AMLN | | In Pictures: Class Of 2010--Short-Sellers
Tue, Nov 24 -
at Forbes.com | | • | AMLN | | [$$] Stocks in the Spotlight Tuesday
Tue, Nov 24 -
at Barrons.com | | • | VVUS | | VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Tue, Nov 24 -
EDGAR Online | | • | VVUS | | 3 Stocks Ready to Roar
Tue, Nov 24 -
at Motley Fool | | • | AMLN | | Amylin Pharms upgraded by Barclays Capital
Tue, Nov 24 -
Briefing.com | | • | VVUS | | The Side Effect of Developing Obesity Drugs
Mon, Nov 23 -
at Motley Fool | | • | VVUS | | Poniard Finds Cash to Keep Lights On: BioBuzz
Mon, Nov 23 -
at TheStreet.com | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
Competitors
